RxDoctor Payments Data

Richard Aguirre, MD

Family Medicine · Lakeville, NYNPI 1821004698

Payments from drug & device makers

$30,888in general payments, 2019–2025

Across 1,988 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$3K
  • Pfizer$2K
  • Lilly USA, LLC$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$2K
  • plus $15K from 54 others

What the payments were for

  • Food & beverage$30,66899%
  • Education$2201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk231$3,426
AstraZeneca150$3,322
Pfizer208$2,487
Lilly USA, LLC169$2,357
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC155$1,959
AbbVie(2 entities)125$1,894
GSK121$1,659
Amgen(2 entities)83$1,316
Supernus Pharmaceuticals, Inc.70$1,282
Boehringer Ingelheim49$852
Bayer52$807
Astellas Pharma US Inc44$699
Merck42$619
Johnson & Johnson60$596
Sanofi-aventis U.S. LLC29$564
Amarin Pharma, Inc.32$474
Novartis24$462
Takeda Pharmaceuticals U.S.A., Inc.36$438
Exact Sciences25$430
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$368
Otsuka America Pharmaceutical, Inc.18$338
Teva Pharmaceuticals USA, Inc.16$336
Lundbeck LLC14$323
Sunovion Pharmaceuticals Inc.24$322
Paratek Pharmaceuticals, Inc.16$290
Kowa Pharmaceuticals America, Inc.12$257
Axsome Therapeutics, Inc.13$248
E.r. Squibb & Sons, L.L.C.16$231
Neurocrine Biosciences, Inc.9$174
Biohaven Pharmaceuticals, Inc.15$162
Bausch Health US, LLC10$160
Sumitomo Pharma America, Inc.6$141
Vanda Pharmaceuticals Inc.5$129
Corium, LLC7$126
Idorsia Pharmaceuticals US Inc7$125
Insulet Corporation6$121
Upsher-smith Laboratories LLC7$110
Biohaven Pharmaceutical Holding Company Ltd.6$96
Kaleo, Inc.5$92
Optinose US, Inc.4$79
Alkermes, Inc.4$79
Abbott4$78
Viatris Specialty LLC4$76
Phathom Pharmaceuticals, Inc.3$72
Lupin Inc.4$69
Shire North American Group Inc3$69
Mylan Specialty L.p.3$66
Inspire Medical Systems, Inc.2$58
Eisai Inc.4$56
Esperion Therapeutics, Inc.3$53
Biogen2$48
Phadia US Inc.2$33
Almatica Pharma LLC2$31
Assertio Therapeutics, Inc.1$23
Jazz Pharmaceuticals Inc.1$23
Genentech USA, Inc.1$23
Edwards Lifesciences1$22
ARS Pharmaceuticals Operations, Inc.1$20
Corcept Therapeutics1$18
Dexcom, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,888 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$90,977
Medicare patients
146
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide207$274,961
JardianceEmpagliflozin251$260,060
EliquisApixaban209$209,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter168$123,229
FarxigaDapagliflozin Propanediol95$111,864
MounjaroTirzepatide86$107,117
RybelsusSemaglutide69$86,499
XareltoRivaroxaban66$69,717
OtezlaApremilast11$50,417
Janumet XrSitagliptin Phos/Metformin Hcl23$36,483
RexultiBrexpiprazole20$27,377
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$26,471
MyrbetriqMirabegron24$22,090
JanuviaSitagliptin Phosphate15$20,651
Synjardy XrEmpagliflozin/Metformin Hcl28$20,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,426$361,460276 claims
Boehringer IngelheimJardiance, Synjardy Xr$852$280,459279 claims
PfizerEliquis, Nurtec Odt, Abrysvo$2,487$240,042272 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$1,659$145,326222 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,322$138,335138 claims
Lilly USA, LLCMounjaro$2,357$107,11786 claims
MerckJanumet Xr, Januvia, Janumet$619$73,80955 claims
Johnson & JohnsonXarelto$596$69,71766 claims
AmgenOtezla$1,316$50,41711 claims
Otsuka America Pharmaceutical, Inc.Rexulti$338$27,37720 claims
Astellas Pharma US IncMyrbetriq$699$22,09024 claims
BayerKerendia$807$9,17211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Lakeville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →